Alnylam Act® Primary Hyperoxaluria Type 1
No-charge genetic testing and counseling program
Alnylam Pharmaceuticals and PreventionGenetics have partnered to offer genetic testing and counseling at no charge for individuals located in the U.S. and Canada who may carry a gene variant known to be associated with primary hyperoxaluria type 1.
The Alnylam Act® program was created to provide access to genetic testing and counseling to patients as a way to help people make more informed decisions about their health.
The Alnylam Act® program offers testing with either of the following panels. Choose a test below to view program details, eligibility criteria, and other important information.
Primary Hyperoxaluria Panel (3 genes)
Test code: 16029
Genes: AGXT, GRHPR, HOGA1
Nephrolithiasis Panel
(45 genes)
Test code: 16035
Genes: ADCY10, AGXT, ALPL, APRT, ATP6V0A4, ATP6V1B1, ATP7B, BSND, CA2, CASR, CLCN5, CLDN16, CLDN19, CLPB, CYP24A1, FAM20A, FOXI1, GNA11, GPHN, GRHPR, HNF4A, HOGA1, HPRT1, KCNJ1, MAGED2, MOCOS, MOCS1, MOCS2, NHERF1, OCRL, PEX6, PREPL, PRPS1, SLC12A1, SLC22A12, SLC26A1, SLC2A9, SLC34A1, SLC34A3, SLC3A1, SLC4A1, SLC7A9, UMOD, VDR, XDH